Latest Earnings Results: Q3 '26
Estimated EPS
$0.00
Reported EPS
---
Surprise
---
Estimated Rev
$103M
Reported Rev
$106M
Surprise
+2.91%
• Reported GAAP EPS of -$0.22 down -300.00% YoY • Reported revenue of $105.77M down -38.93% YoY • Alvotech management anticipates total revenues to be in the range of $650-$700 million and adjusted EBITDA to be in the range of $180-220 million for the full year of 2026.
Bullish Takeaway
Alvotech advanced its regulatory pipeline with multiple biosimilar application resubmissions, secured a VAI classification for its manufacturing facility, and bolstered its financial position through new equity and debt financing.
Bearish Takeaway
Alvotech experienced a decline in H1 2026 financial performance, with adjusted total revenue and EBITDA decreasing compared to the prior year, driven by manufacturing improvement programs that impacted output and availability.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.00 | -- | -- | N/A |
Q2 '26 | -$0.05 | -- | -- | N/A |
Q1 '26 | -$0.05 | -$0.09 | -91.50% | MISSED |
Q4 '25 | -$0.01 | -- | -- | N/A |
Q3 '25 | -$0.03 | -$0.10 | -275.56% | MISSED |